Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis

Phase 1WithdrawnNCT02242071

Neurogen Brain and Spine Institute

Overview

The effect of autologous bone marrow mononuclear cells on Motor Neuron Disease/Amyotrophic Lateral Sclerosis patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Amyotrophic Lateral Sclerosis

Interventions

Stem CellBIOLOGICAL

intrathecal autologous bone marrow mononuclear cell transplantation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with the diagnosis of definite Motor Neuron Disease/amyotrophic lateral sclerosis. * Age 18-80 years Exclusion Criteria: * HIV/HBV/HCV * Malignancies * Bleeding tendencies * Pneumonia * Renal failure * Severe liver dysfunction * Severe anemia \[hb \< 8\] * Any bone marrow disorder * Space occupying lesion in brain * Pregnancy and lactation * Other acute medical conditions/infections such as respiratory infection and pyrexia * left ventricular ejection fraction \< 25% * Patient on artificial ventilatory support

Locations (1)

Neurogen brain and spine institute

Navi Mumbai, Maharashtra, India

Outcomes

Primary Outcomes

Amyotrophic Lateral Sclerosis Functional rating scale-revised

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.